Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kunming Sinoway Natural Pharmaceuticals Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This 1 pending office action is assigned to 1 distinct art unit, showing a singular technical focus for the company's current prosecution activity.
The prosecution involves 1 distinct examiner, BERHANE, SELAM. This busiest examiner is responsible for 1 pending office action, which is the only active matter for the company. This means BERHANE, SELAM is the sole examiner currently reviewing the company's patent applications.
With 1 distinct examiner and 1 distinct art unit, the prosecution landscape is very concentrated. Practitioners should focus on the specific examination style of BERHANE, SELAM, as there are no other pending actions to provide a broader perspective. This focus on 1 art unit reflects a specific technical direction within the pharmaceutical sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028200 | HUMANIZED ANTI-CD22 RECOMBINANT IMMUNOTOXIN AND APPLICATION THEREOF | BERHANE, SELAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028200 | HUMANIZED ANTI-CD22 RECOMBINANT IMMUNOTOXIN AND APPLICATION THEREOF | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18028200 | HUMANIZED ANTI-CD22 RECOMBINANT IMMUNOTOXIN AND APPLICATION THEREOF | BERHANE, SELAM | 1675 | §102§112 | Final Rejection | — | Pending | Mar 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial